FDA Class III Recall: ANI Pharmaceuticals' Labeling Error on Mixed Amphetamine Salts Impacts Supply
ANI Pharmaceuticals, Inc. initiated a Class III recall (D-0047-2021) for 6,780 bottles of Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules due to an incorrect 24-month expiration date instead of 18 months. This event highlights critical quality control lapses in labeling for a key CNS stimulant, impacting procurement and regulatory compliance for Amerigen Pharmaceuticals, Inc. and distributors nationwide.
FDA Class III Recall: ANI Pharmaceuticals' Labeling Error on Mixed Amphetamine Salts
ANI Pharmaceuticals, Inc., based in Baudette, MN, United States, initiated a voluntary Class III recall, designated D-0047-2021, for 6,780 bottles of Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules, 25 mg. This action, initiated on October 9, 2020, and terminated on January 19, 2022, was prompted by a critical labeling error: the product was incorrectly marked with a 24-month expiration date instead of the correct 18-month period. Specifically, Lot 19T16 bore an expiration date of January 2022, which was six months beyond its actual shelf life. The affected product, manufactured for Amerigen Pharmaceuticals, Inc. of Lyndhurst, NJ, was distributed nationwide across the USA. For procurement directors and supply chain VPs, this incident underscores the imperative of stringent quality control oversight for contract manufacturing partners. An incorrect expiration date, even if classified as Class III (unlikely to cause adverse health consequences), can lead to subpotent medication being dispensed, eroding patient trust and exposing distributors and pharmacies to compliance risks. Businesses must ensure their supplier qualification processes include rigorous audits of labeling and batch release procedures to prevent similar costly disruptions.
ANI Pharmaceuticals' Role in Generic CNS Stimulant Supply Chain
ANI Pharmaceuticals, Inc. operates from its facility in Baudette, MN, serving as a manufacturer of human prescription drugs. This recall specifically involved a generic version of a widely used central nervous system (CNS) stimulant, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules, 25 mg. The product was explicitly manufactured for Amerigen Pharmaceuticals, Inc., indicating ANI Pharmaceuticals' role as a contract manufacturing organization (CMO) within the pharmaceutical supply chain. This relationship means that Amerigen Pharmaceuticals, Inc. relies on ANI for the production and quality assurance of this specific drug product. For business development executives and supply chain VPs, this event highlights the inherent risks in outsourcing manufacturing. The quality control lapse at ANI Pharmaceuticals directly impacted Amerigen's product integrity and market availability. Companies engaging CMOs must implement robust vendor management programs that extend beyond initial qualification to continuous monitoring of quality systems, particularly those governing critical attributes like expiration dating and labeling accuracy, to safeguard their brand reputation and ensure uninterrupted supply of essential medications.
Market Impact and Supply Chain Vulnerabilities for Dextroamphetamine Products
The recall of 6,780 bottles of Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules, 25 mg, distributed nationwide in the USA, represents a tangible, albeit contained, disruption to the supply chain for this critical CNS stimulant. While a Class III recall suggests a low probability of adverse health consequences, the withdrawal of nearly 6,800 units from the market can still strain inventory levels for pharmacies and distributors. For regulatory affairs heads, managing such a recall involves significant logistical and compliance burdens, including communication with regulatory bodies, managing product returns, and ensuring proper disposition of affected stock. This incident exposes a vulnerability in the supply chain where a single manufacturing error can necessitate a nationwide recall, impacting patient access and increasing operational costs for all downstream stakeholders. Procurement directors must assess their inventory resilience and contingency plans for generic amphetamine products, especially those sourced from third-party manufacturers, to mitigate the impact of similar future events and maintain consistent supply to the market.
Strategic Sourcing: Diversifying Supply for Mixed Amphetamine Salts
In light of the ANI Pharmaceuticals recall, procurement directors responsible for sourcing generic Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate products must critically evaluate their supplier diversification strategies. While the specific recall was resolved, it serves as a clear indicator of potential vulnerabilities when relying on a single manufacturing source or a limited pool of suppliers for critical drug components or finished products. The market for generic CNS stimulants is competitive, and identifying alternative, FDA-approved manufacturers with robust quality systems is paramount. Companies should proactively engage in the qualification of secondary and tertiary suppliers, even for products with a Class III recall history, to build resilience against future disruptions. This proactive approach minimizes the commercial impact of quality control issues at any single facility, ensuring continuity of supply and reducing the risk of market shortages. Regulatory affairs teams should also be involved in assessing the regulatory standing and compliance history of potential alternative suppliers to ensure they meet all necessary quality and manufacturing standards.
Regulatory Compliance Post-Recall: Scrutiny for ANI Pharmaceuticals
Although the Class III recall (D-0047-2021) initiated by ANI Pharmaceuticals, Inc. was terminated on January 19, 2022, signifying the completion of the recall activities, the event remains a part of the company's regulatory record. For regulatory affairs heads, any recall, regardless of classification, signals a lapse in Good Manufacturing Practices (GMP) and can trigger increased scrutiny from the FDA during future inspections of the Baudette, MN facility. The root cause of the incorrect expiration date—whether a documentation error, a training deficiency, or a systemic failure in quality control processes—must be thoroughly investigated and robust corrective and preventive actions (CAPAs) implemented. Procurement teams conducting supplier audits should specifically inquire about these CAPAs, seeking evidence of improved label control, batch record review, and quality assurance procedures. While the provided intelligence does not detail a prior regulatory history for ANI Pharmaceuticals, this incident will undoubtedly inform future FDA oversight, potentially leading to more rigorous inspections and a closer examination of their quality management systems for all products, including those manufactured for partners like Amerigen Pharmaceuticals, Inc.
Remediation and Long-Term Implications for ANI Pharmaceuticals' Operations
The termination of the D-0047-2021 recall indicates that ANI Pharmaceuticals, Inc. has completed the necessary actions to address the specific lot of Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules. This typically involves retrieving affected product, correcting the labeling issue, and implementing immediate corrective measures. However, the long-term implications for ANI Pharmaceuticals extend to the need for systemic improvements in their quality management system. For business development executives, maintaining a strong regulatory compliance record is crucial for securing and retaining contract manufacturing agreements. Future partners, including those like Amerigen Pharmaceuticals, Inc., will scrutinize ANI's response to this recall, looking for evidence of comprehensive CAPAs that prevent recurrence. Regulatory affairs teams within ANI must ensure that the underlying causes of the labeling error are fully resolved, potentially through enhanced employee training, updated Standard Operating Procedures (SOPs) for labeling and batch release, and more robust quality assurance checks. Demonstrating a proactive and effective remediation strategy is essential for rebuilding trust and ensuring continued market access for their products manufactured in Baudette, MN.